Lantheus Announces Share Repurchase Program

Core Viewpoint - Lantheus Holdings, Inc. has authorized a share repurchase program of up to $250 million over the next twelve months, reflecting confidence in its leadership in the radiopharmaceutical sector and commitment to shareholder value [1][2]. Company Overview - Lantheus is a leading company focused on radiopharmaceuticals, dedicated to enabling clinicians to Find, Fight, and Follow disease for improved patient outcomes. The company has been providing radiopharmaceutical solutions for over 65 years and is headquartered in Massachusetts with offices in Canada and Sweden [3]. Share Repurchase Program - The share repurchase program is set to commence in the fourth quarter of the current year, with the intention to return capital to shareholders while pursuing business development to expand its radiopharmaceutical portfolio [2]. - Repurchases may occur through open market transactions, privately negotiated transactions, and other legally permissible means, depending on market conditions [2]. - The actual timing, number, and dollar amount of repurchase transactions will be determined at the company's management's discretion, influenced by various factors including the market price of the common stock [2].